HomeCompareSARTF vs VIG

SARTF vs VIG: Dividend Comparison 2026

SARTF yields 0.37% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SARTF wins by $291.6K in total portfolio value· pulled ahead in Year 6
10 years
SARTF
SARTF
● Live price
0.37%
Share price
$226.33
Annual div
$0.84
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$323.8K
Annual income
$213,389.35
Full SARTF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — SARTF vs VIG

📍 SARTF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSARTFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SARTF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SARTF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SARTF
Annual income on $10K today (after 15% tax)
$31.55/yr
After 10yr DRIP, annual income (after tax)
$181,380.95/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, SARTF beats the other by $181,232.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SARTF + VIG for your $10,000?

SARTF: 50%VIG: 50%
100% VIG50/50100% SARTF
Portfolio after 10yr
$178.1K
Annual income
$106,782.27/yr
Blended yield
59.97%
📊

Analyst Conviction Gap

Where Wall Street is split right now

SARTF
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
Altman Z
2.3
Piotroski
6/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SARTF buys
0
VIG buys
9
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$VIG▲ Buy$1,001 - $15,0002024-05-16
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002023-12-28
Ro Khanna🏢 House$VIG▼ Sell$15,001 - $50,0002023-05-04
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
Joe Courtney🏢 House$VIG▼ Sell$1,001 - $15,0002020-10-09
K. Michael Conaway🏢 House$VIG▼ Sell$50,001 - $100,0002020-09-08
K. Michael Conaway🏢 House$VIG▲ Buy$15,001 - $50,0002020-05-19
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSARTFVIG
Forward yield0.37%1.61%
Annual dividend / share$0.84$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%0%
Portfolio after 10y$323.8K$32.3K
Annual income after 10y$213,389.35$175.21
Total dividends collected$294.5K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SARTF vs VIG ($10,000, DRIP)

YearSARTF PortfolioSARTF Income/yrVIG PortfolioVIG Income/yrGap
1$10,774$74.23$11,301$160.59$527.00VIG
2$11,678$149.49$12,752$162.91$1.1KVIG
3$12,798$302.85$14,370$165.02$1.6KVIG
4$14,314$620.38$16,176$166.93$1.9KVIG
5$16,613$1,296.96$18,188$168.67$1.6KVIG
6← crossover$20,590$2,813.57$20,432$170.25+$158.00SARTF
7$28,549$6,517.78$22,933$171.68+$5.6KSARTF
8$47,439$16,892.03$25,720$172.98+$21.7KSARTF
9$103,226$52,465.87$28,827$174.15+$74.4KSARTF
10$323,841$213,389.35$32,288$175.21+$291.6KSARTF

SARTF vs VIG: Complete Analysis 2026

SARTFStock

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Full SARTF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this SARTF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SARTF vs SCHDSARTF vs JEPISARTF vs OSARTF vs KOSARTF vs MAINSARTF vs DGROSARTF vs NOBLSARTF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.